Neuropathic Pain Model of Peripheral Neuropathies Mediated by Mutations of Glycyl-tRNA Synthetase

Seo Jin Lee,* Ah Jung Seo,* Byung Sun Park, Hyun Woo Jo, and Youngbum Huh

INTRODUCTION

Neuropathic pain is a common consequence of damage to the nervous system via the mechanisms of infection, nerve injury, diabetes, and so forth (1). Many recent studies have employed diverse animal models of neuropathic pain, and indicate that the abnormal excitability of dorsal horn neurons and the activation of spinal microglia by peripheral sensory input influence the induction of neuropathic pain (2-5).

Charcot-Marie-Tooth disease (CMT) is the most common inherited motor and sensory neuropathy. Previous studies have found that, according to CMT patients, neuropathic pain is an occasional symptom of CMT. However, neuropathic pain is not considered to be a significant symptom associated with CMT and, as a result, no studies have investigated the pathophysiology underlying neuropathic pain in this disorder. Thus, the first animal model of neuropathic pain was developed by our laboratory using an adenovirus vector system to study neuropathic pain in CMT. To this end, glycyl-tRNA synthetase (GARS) fusion proteins with a FLAG-tag (wild type [WT], L129P and G240R mutants) were expressed in spinal cord and dorsal root ganglion (DRG) neurons using adenovirus vectors. It is known that GARS mutants induce GARS axonopathies, including CMT type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V). Additionally, the morphological phenotypes of neuropathic pain in this animal model of GARS-induced pain were assessed using several possible markers of pain (Iba1, pERK1/2) or a marker of injured neurons (ATF3). These results suggest that this animal model of CMT using an adenovirus may provide information regarding CMT as well as a useful strategy for the treatment of neuropathic pain.

Keywords: Charcot-Marie-Tooth Disease; Neuralgia; Glycyl-tRNA Ligase; ATF3 Protein Mouse; Microglia; Adenoviridae

MATERIALS AND METHODS

Animals

All experiments were performed using 6-week-old male C57BL/6...
mice, which were obtained from Semtako (Osan, Korea). All subjects were housed in a temperature- and humidity-controlled environment on a 12-hr light/dark cycle, provided food and water ad libitum, and had their cages were changed weekly.

Neuron-specific recombinant adenoviruses

The mouse choline acetyltransferase (ChAT) gene (GenBank accession number NC_000080) was used as the promoter, and included the neuron-restrictive silencer element (NRSE) and a cholinergic-specific enhancer, which are key regulatory elements for neuron-specific expression (18, 19). The use of human GARS (hGARS) clones allowed for subcloning into the pAdTrack-ChAT-CMV/GFP vector. The E1/E3 double-deleted supercoiled adenoviral backbone vector (pAdEasy-1; Stratagene; Santa Clara, CA, USA) was used to generate stable homologous recombinants with pAdTrack-ChAT-hGARS\(^{wt}\)-CMV/GFP, pAdTrack-ChAT-hGARS\(^{G240R}\)-CMV/GFP, and pAdTrack-ChAT-hGARS\(^{L129P}\)-CMV/GFP (Fig. 1A). The titers of Ad\(h\)-ChAT, Ad\(h\)-GARS\(^{wt}\)/ChAT, Ad\(h\)-GARS\(^{G240R}\)/ChAT, and Ad\(h\)-GARS\(^{L129P}\)/ChAT employed in these experiments were 3.2 \(\times\) 10\(^9\), 5.1 \(\times\) 10\(^9\), 4.9 \(\times\) 10\(^9\), and 2.6 \(\times\) 10\(^9\) pfu/mL, respectively.

Viral administration procedures

Recombinant adenoviruses were injected into the sciatic nerve. Mice were anesthetized with 30 mg/kg Zoletil (Virbac; Carros Sedecs, France) and 10 mg/kg Rompun (Bayer; Leverkusen, Germany) before the sciatic nerve was surgically exposed via an incision of the musculus gluteus superficialis. This virus diluent of Ad\(h\)-GARS\(^{wt}\)/ChAT (1.5 \(\mu\)L), Ad\(h\)-GARS\(^{G240R}\)/ChAT (1.5 \(\mu\)L), or Ad\(h\)-GARS\(^{L129P}\)/ChAT (3 \(\mu\)L) containing 0.1% fast green as a tracer was then injected into the sciatic nerves using a Hamilton syringe with a glass micropipette under a stereoscope. The skin incision was closed with Silkam 4.0 sutures (B/Braun; Melsungen, Germany).

Immunofluorescence staining

DRG neuron and spinal cord tissue slides were fixed in 4% paraformaldehyde (PFA) for 10 min. Following three washes in phosphate-buffered saline (PBS), the E1/E3 double-deleted supercoiled adenoviral backbone vector (pAdEasy-1; Stratagene; Santa Clara, CA, USA) was used to generate stable homologous recombinants with pAdTrack-ChAT-hGARS\(^{wt}\)-CMV/GFP, pAdTrack-ChAT-hGARS\(^{G240R}\)-CMV/GFP, and pAdTrack-ChAT-hGARS\(^{L129P}\)-CMV/GFP (Fig. 1A). The titers of Ad\(h\)-ChAT, Ad\(h\)-GARS\(^{wt}\)/ChAT, Ad\(h\)-GARS\(^{G240R}\)/ChAT, and Ad\(h\)-GARS\(^{L129P}\)/ChAT employed in these experiments were 3.2 \(\times\) 10\(^9\), 5.1 \(\times\) 10\(^9\), 4.9 \(\times\) 10\(^9\), and 2.6 \(\times\) 10\(^9\) pfu/mL, respectively.

Western blotting

The DRG neurons or spinal dorsal horn tissues were lysed in a modified radioimmune precipitation assay buffer (RIPA; 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 0.5% deoxycholic acid, 2 \(\mu\)g/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride, 5 mM benzamidine, 1 mM sodium orthovanadate, and 1 \(\times\) protease inhibitor cocktail [Roche; Indianapolis, IN, USA]). Protein extracts were separated using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then electrotransferred onto a nitrocellulose membrane. After blocking with 5% non-fat milk in Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBST) overnight, the membrane was incubated with the following primary antibodies for 1 hr at room temperature; mouse anti-beta...
RESULTS

Based on previous research, it is known that the GARS mutant proteins L129P and G240R are involved in dSMA-V and CMT2D, respectively (10, 12, 21). To develop CMT2D and dSMA-V animal models of neuropathic pain, an adenovirus vector system was employed. Recombinant adenoviruses (pAdeasy-ChAT-hGARS-FLAG-CMV-GFP) that expressed the FLAG-tagged hGARS protein under the control of the cell-type-specific ChAT promoter and the green fluorescent protein (GFP) gene under the control of the general CMV promoter were used to transfet the sciatic nerves of mice to construct WT and L129P/G240R mutant hGARS-overexpressing mouse models (Fig. 1A). Around the injected site, both Schwann cells and peripheral axons were transfected by adenovirus vectors and expressed the GFP fluorescence, but FLAG was only expressed in peripheral axons due to the neuron-specific promoter (data not shown). However, in the spinal cord, the GFP fluorescence was only expressed in the peripheral projection-related neurons, but not spinal glial cells. To assess the expression of adenovirus vectors in the spinal cord, immunolabeling was performed using an anti-FLAG antibody to detect the expression of transfected WT, L129P and G240R GARS genes. Because GFP in an adenovirus vector is a separate transcript driven by the CMV promoter, all adenovirus vectors (WT, L129P, G240R and an empty vector without GARS gene) exhibited GFP-positive signals in the spinal cord (Fig. 1B). Fig. 1B also indicated the transfection was equally accomplished in both GARS WT- and mutant-expressing sides similar to loading control using β-actin in western blotting. However, the patterns of anti-FLAG immunostaining in the spinal cord are different for each adenovirus vector. Because the empty virus vector contains only the ChAT promoter, it cannot express GARS-FLAG fusion protein as do the other adenovirus vectors (Fig. 1B); WT, G240R- and L129P-expressed portions of the spinal cord exhibited anti-FLAG signals in neuronal cell bodies. Additionally, immunostaining for FLAG demonstrated the presence of GFP/FLAG double positive axons, which indicates that the adenovirus vectors effectively expressed GARS proteins (Fig. 1A). Thus, these findings suggest neuron-specific expression of the FLAG-tagged hGARS fusion protein in peripheral neurons.

Recent studies have demonstrated the role of activated microglia in chronic neuropathic pain (5, 22, 23). When allodynia is apparent, the number of microglia on the injured side of spinal cord identified by microglial markers increases dramatically (4, 17). To evaluate the spatial extent of these activated microglia relative to the mutant GARS protein in the spinal dorsal horn, Iba1 immunoreactivity, as a marker of activated microglia, was compared between WT GARS- and mutant GARS-expressing portion of the spinal dorsal horn. A significant increase in the number of microglia was observed in the L129P and G240R mutant GARS-expressing portions relative to the WT GARS-express-
ing portion (Fig. 2A, B). To minimize the differences in the expression of each viral vector-induced GARS protein (WT, L129P, and G240R), the differences were compensated by determining GFP expression by means of assaying Iba1 expression (Fig. 2B). Thus, these findings indicate that the expression of mutant L129P and G240R GARS in the central axon terminals of the spinal cord increases the number of activated microglia, which is sufficient to induce neuropathic pain in a model of mutant GARS-induced neuropathy.

p44/42 MAPK (ERK1/2) is a member of the MAPK family that plays a critical role in intracellular signal transduction. Following peripheral nerve damage, microglia in the spinal dorsal horn express ERK, which contributes to the induction of neuropathic pain (24, 25). To determine whether ERK activation is involved in the mutant GARS-expressing portions of the spinal dorsal horn, Western blotting was performed on spinal dorsal horn samples using anti-pERK1/2 (Fig. 3A). A significant activation of ERK1/2 in the mutant GARS-expressing dorsal horn samples was observed compared to WT GARS-expressing samples (Fig. 3A). Both pERK1 (p44 MAPK) and pERK2 (p42 MAPK) levels were increased significantly in the mutant GARS expressing

**Fig. 2.** Increased number of microglia in the GARS-mutant-expressed dorsal horn. (A) Increase in the number of Iba1-positive microglia in the dorsal horn of the L5-spinal cord 7 days after the transfection of adenovirus vectors into sciatic nerves. GFP expression (green) and immunofluorescence labeling of Iba1 (red) were identified in spinal cord cross-sections. Lower panels are higher magnification images of the spinal dorsal horn. Middle two panels indicates the high magnification images of the upper panels (arrows). Scale bar = 500 μm. (B) Quantification of activated microglia in the dorsal horn at Day 7. The number of Iba1 was calculated with the correction using GFP-neuronal bodies in spinal cord. *P < 0.001 compared with GARS WT (WT, n = 5; L129P, n = 5; G240R, n = 4). (C) mRNA expression of FLAG-tag in the spinal cord following infection with GARS-WT-expressing adenoviruses by RT-PCR.

**Fig. 3.** GARS mutant proteins induce ERK activation in the spinal cord. (A) Western blotting revealed an increase in both pERK1 (p44 MAPK) and pERK2 (p42 MAPK) in the L5-spinal cord. FLAG was the adenovirus vector-expressing control. (B) Quantification of pERK1 and pERK2 levels in the L5-spinal cord; pERK1/2 levels were normalized to FLAG levels. *P < 0.001 compared to the WT, n = 4. (C) GARS mutants L129P and G240R induced a significant decrease in paw withdrawal threshold in virus-infected mice compared with Empt- and GATS-WT-expressing mice. Empt, empty virus without insert. n = 4.
dorsal horn compared with WT GARS-expressing samples (Fig. 3B). To investigate the role of GARS mutation in the pathogenesis of pain hypersensitivity, we compared the pain behaviors of WT-, Empt-, G240R-, and L129P-expressing mice. Immediately after the sciatic nerves were infected with the adenovirus, WT, Empt, G240R, and L129P mutant hGARS-expressing mice showed a significant decrease in PWT (Fig. 3C). Over time, however, the WT-GARS- and Empt-expressing mice exhibited significantly improved PWT compared with the G240R- and L129P-expressing mice and the allodynia behavior in G240R- and L129P-expressing mice was unchanged for 7 days after adenovirus infection (Fig. 3C). In addition, the duration of the pain in this model is less than 3 weeks (Fig. 2C) because of in vivo immune reaction to adenovirus. Thus, these results suggest that mutant GARS (L129P and G240R) expression in axon terminals of the spinal dorsal horn may mediate ERK1/2 activation and be involved in the development of neuropathic pain.

To identify the pathophysiological mechanisms underlying neuropathic pain, several studies have monitored the induction of ATF3, a selective marker of nerve injury (14, 15, 26). These studies found that stimuli in the peripheral nerves induce the expression of ATF3 in DRG neurons in animal models of neuropathic pain, suggesting that ATF3 has a significant influence on neuropathic pain. Here, ATF3 was also utilized as a possible marker of sensory damage that affects neuropathic pain in mutant GARS-induced neuropathies. A previous report found that immunohistochemically stained ChAT could be visualized in the myelinated A-fibers and unmyelinated C-fibers of the adult rat DRG neurons (27, 28). To identify the expression of GARS fusion proteins in DRG neurons, the expression of the viral protein FLAG was examined in DRG tissues by Western blotting and RT-PCR (Fig. 4A, B). FLAG expression was confirmed in DRG neurons following viral vector transfection into the sciatic nerves (Fig. 4A, B). To assess ATF3 activation in mutant-GARS-expressing DRG neurons compared with WT-GARS-expressing neurons, DRG tissues were immunostained with an anti-ATF3 antibody. ATF3 staining identified an increased amount of mutant-GARS-expressing (L129P and G240R) DRG neurons compared with WT-GARS-expressing neurons (Fig. 4C). ATF3 staining was strong in the area detected by GFP green fluorescence in mutant-GARS-expressing DRG neurons, but no ATF3-positive signals were detected in WT-GARS-expressing DRG neurons (Fig. 4C). Quantitative analyses also revealed an increase in the number of ATF3-positive signals in the area positive for GFP fluorescence in mutant-GARS-expressing DRG neurons compared with WT-GARS-expressing DRG neurons. Thus, these data suggest that mutant GARS protein expression in DRG sensory neurons may be involved in ATF3 activation and that the central axon terminals of DRG neurons associated with ATF3 activation may affect the recruitment of microglia and contribute to the initiation of neuropathic pain in mutant GARS-induced neuropathies.

**DISCUSSION**

Interestingly, previous studies have shown the in vitro and in vivo distribution defect of GARS mutants in the axons, but not cell body (29, 30). In Fig. 2A, middle two high magnification im-
ages showed that the expression of GFP fluorescence in the dorsal horn was only accomplished in the GARS WT-expressing central processes of DRG neurons whose peripheral axons were infected by adeno virus vectors, but did not in the GARS mutant-expressing dorsal horn.

Damage to the peripheral nervous system induced by CMT can result in neuropathic pain, which is difficult to manage effectively. To date, studies of CMT have focused primarily on basic genetic analyses related to the cause of this disease and on some clinically relevant symptoms; thus, less is known regarding the important role of neuropathic pain. However, a growing amount of evidence indicates that pain in CMT is occasional and that the clinically pain is most often neuropathic (7-9). We developed the animal model of CMT-related neuropathic pain (CMT2D and dSMa-V) using adeno virus vectors. Following the transfection of GARS WT-, L129P-, and G240R-expressing virus vectors into the sciatic nerve, the equal expression of GARS WT, L129P, and G240R fusion proteins was confirmed via FLAG-tag expression in each portion of the spinal dorsal horn (Fig. 1B). Additionally, this study demonstrated that GARS mutants are morphologically involved in neuropathic pain using Iba1, ATF3, and pERK1/2, possible markers of neuropathic pain. Although further evaluation is necessary to optimize this animal model of neuropathic CMT pain, it seems likely that this type of model may be able to explain the morphological phenotypes of neuropathic pain associated with CMT. Therefore, this animal model may help to identify the molecular mechanisms underlying neuropathic pain in CMT diseases and represent a new approach to discovery of therapeutic targets.

ACKNOWLEDGMENTS

We thank Prof. Junyang Jung (Department of Anatomy and Neurobiology, Kyung Hee University, Seoul, Korea), Dr. Doyeun Kim (Medicinal Bioconvergence Research Center, Seoul National University, Seoul, Korea) for valuable discussion and Dr. Paul Schimmel (Scripps Research Institute, La Jolla, CA, USA) for kindly providing the WT and L129P mutant GARS clones.

DISCLOSURE

The authors have no conflict of interest to disclose.

ORCID

Seo Jin Lee  http://orcid.org/0000-0001-6531-0526
Ah Jung Seo  http://orcid.org/0000-0002-5211-3213
Byung Sun Park  http://orcid.org/0000-0001-6131-6808
Hyun Woo Jo  http://orcid.org/0000-0002-8984-8694
Youngbuhm Huh  http://orcid.org/0000-0002-7687-0374

REFERENCES

1. Baron R. Mechanisms of disease: neuropathic pain: a clinical perspective. Nat Clin Pract Neurol 2006; 2: 95-106.
2. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288: 1765-9.
3. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32: 1-32.
4. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003; 424: 778-83.
5. Tsuda M, Inoue K, Salter MW. Neuropathic pain and spinal microglia: a big problem from molecules in “small” glia. Trends Neurosci 2005; 28: 101-7.
6. Emery AE. Population frequencies of inherited neuromuscular diseases: a world survey. Neuromusc Disord 1991; 1: 19-29.
7. Carter GT, Jensen MP, Galer BS, Kraft GH, Crabtree LD, Beardsley RM, Abresch RT, Bird TD. Neuropathic pain in Charcot-Marie-Tooth disease. Arch Phys Med Rehabil 1996; 79: 1560-4.
8. Pazzaglia C, Vollono C, Ferraro D, Virdis D, Lupi V, Le Pera D, Tonali P, Padula L, Valeriani M. Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: a laser-evoked potential study. Pain 2010; 149: 379-85.
9. Ribiere C, Bernardin M, Sacconi S, Delmont E, Fournier-Mehouas M, Rauscet H, Benchortane M, Staccini P, Lantéri-Minet M, Desmoule C. Pain assessment in Charcot-Marie-Tooth (CMT) disease. Ann Phys Rehabil Med 2012; 55: 160-73.
10. Antonellis A, Ellsworth RE, Sambuughin N, Puls I, Abel A, Lee-Lin SQ, Jordanova A, Kremensky I, Christodoulou K, Middleton LT, et al. Glycyrrhiza tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003; 72: 1293-9.
11. Sambuughin N, Sivakumar K, Selenge B, Lee HS, Friedlich D, Baasanjav D, Dalakas MC, Goldfarb LG. Autosomal dominant distal spinal muscular atrophy type V (dSMa-V) and Charcot-Marie-Tooth disease type 2D (CMT2D) segregate within a single large kindred and map to a refined region on chromosome 7p15. J Neurol Sci 1998; 161: 23-8.
12. Ionasescu V, Searby C, Sheffield VC, Rokina T, Nishimura D, Ionasescu R. Autosomal dominant Charcot-Marie-Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet 1996; 5: 1373-5.
13. Motley WW, Talbot K, Fischbeck KH. GARS axonopathy: not every neuron’s cup of tRNA. Trends Neurosci 2010; 33; 59-66.
14. Bráz JM, Basbaum AI. Differential AT3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuli. Pain 2010; 150: 290-301.
15. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, Read SJ. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain 2007; 128: 272-82.
16. Ma W, Quirion R. Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain 2002; 99: 175-84.
17. Maeda M, Tsuda M, Tozaki-Saitoh H, Inoue K, Kiyama H. Nerve injury-activated microglia engulf myelinated axons in a P2Y12 signaling-de-
pendent manner in the dorsal horn. Glia 2010; 58: 1838-46.
18. Misawa H, Ishii K, Deguchi T. Gene expression of mouse choline acetyltransferase. Alternative splicing and identification of a highly active promoter region. J Biol Chem 1992; 267: 20392-9.
19. Lönnerberg P, Schoenherr CJ, Anderson DJ, Ibáñez CE. Cell type-specific regulation of choline acetyltransferase gene expression: role of the neuron-restrictive silencer element and cholinergic-specific enhancer sequences. J Biol Chem 1996; 271: 33358-65.
20. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53: 55-63.
21. Christodoulou K, Kyriakides T, Hristova AH, Georgiou DM, Kalaydjieva L, Yshpekova B, Ivanova T, Weber JL, Middleton LT. Mapping of a distal form of spinal muscular atrophy with upper limb predominance to chromosome 7p. Hum Mol Genet 1995; 4: 1629-32.
22. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci 2005; 6: 521-32.
23. Watkins LR, Maier SE. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003; 2: 973-85.
24. Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005; 114: 149-59.
25. Ma W, Quirion R. Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain 2002; 99: 175-84.
26. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, Yonenobu K, Ochi T, Noguchi K. Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 2000; 15: 170-82.
27. Bellier JP, Kimura H. Acetylcholine synthesis by choline acetyltransferase of a peripheral type as demonstrated in adult rat dorsal root ganglion. J Neurochem 2007; 101: 1607-18.
28. Matsumoto M, Xie W, Inoue M, Ueda H. Evidence for the tonic inhibition of spinal pain by nicotinic cholinergic transmission through primary afferents. Mol Pain 2007; 3: 41.
29. Nangle LA, Zhang W, Xie W, Yang XL, Schimmel P. Charcot-Marie-Tooth disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite distribution defect. Proc Natl Acad Sci U S A 2007; 104: 11239-44.
30. Seo AJ, Shin YH, Lee SJ, Kim D, Park BS, Kim S, Choi KH, Jeong NY, Park C, Jang IV, et al. A novel adenoviral vector-mediated mouse model of Charcot-Marie-Tooth type 2D (CMT2D). J Mol Histol 2014; 45: 121-8.